Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV‐1 RNase H inhibitors. (24th January 2019)
- Record Type:
- Journal Article
- Title:
- Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV‐1 RNase H inhibitors. (24th January 2019)
- Main Title:
- Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV‐1 RNase H inhibitors
- Authors:
- Gao, Ping
Wang, Xueshun
Sun, Lin
Cheng, Xiqiang
Poongavanam, Vasanthanathan
Kongsted, Jacob
Álvarez, Mar
Luczkowiak, Joanna
Pannecouque, Christophe
De Clercq, Erik
Lee, Kuo‐Hsiung
Chen, Chin‐Ho
Liu, Huiqing
Menéndez‐Arias, Luis
Liu, Xinyong
Zhan, Peng - Abstract:
- Abstract: Human immunodeficiency virus (HIV) reverse transcriptase (RT)‐associated ribonuclease H (RNase H) remains as the only enzyme encoded within the viral genome not targeted by current antiviral drugs. In this work, we report the design, synthesis, and biologic evaluation of a novel series of galloyl derivatives with HIV‐1 RNase H inhibitory activity. Most of them showed IC50 s at sub‐ to low‐micromolar concentrations in enzymatic assays. The most potent compound wasII ‐25 that showed an IC50 of 0.72 ± 0.07 μM in RNase H inhibition assays carried out with the HIV‐1BH 10 RT.II ‐25 was 2.8 times more potent than β‐thujaplicinol in these assays. Interestingly, II ‐25 and other galloyl derivatives were also found to inhibit the HIV IN strand transfer activity in vitro. Structure–activity relationships (SAR) studies and molecular modeling analysis predict key interactions with RT residues His539 and Arg557, while providing helpful insight for further optimization of selected compounds. Abstract : A series of galloyl derivatives was designed and synthesized as anti‐HIV‐1 RNase H inhibitors, the most potent compound of which showed an IC50 of 0.72 ± 0.07 μM, 2.8 times more potent than β‐thujaplicinol. SAR studies and molecular modeling analysis provided helpful insight for further optimization of selected compounds.
- Is Part Of:
- Chemical biology & drug design. Volume 93:Number 4(2019)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 93:Number 4(2019)
- Issue Display:
- Volume 93, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 93
- Issue:
- 4
- Issue Sort Value:
- 2019-0093-0004-0000
- Page Start:
- 582
- Page End:
- 589
- Publication Date:
- 2019-01-24
- Subjects:
- galloyl derivatives -- HIV‐1 -- RNase H inhibitors
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.13455 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11759.xml